Ignite Creation Date:
2024-05-06 @ 2:15 PM
Last Modification Date:
2024-10-26 @ 1:28 PM
Study NCT ID:
NCT04265872
Status:
RECRUITING
Last Update Posted:
2023-11-30
First Post:
2020-01-23
Brief Title:
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Sponsor:
Organization:
Baylor Research Institute
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
20
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| EARLY_PHASE1 |
Observational Models:
Time Perspective List:
Who Masked List: